Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16191 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Chia-Ming Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Aspirin, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chung Shan Medical University Hospital.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To examine the cardiovascular safety of combining glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with aspirin in individuals with obesity, both with and without type 2 diabetes (T2D). Materials and Methods This propensity score matched cohort study analysed data from 2 946 579 individuals with obesity, with and without T2D, using the TriNetX US and Global dataset. Participants were categorized into four matched groups: those receiving GLP‐1 RA plus aspirin versus those receiving GLP‐1 RA alone, for both diabetic and non‐diabetic individuals. Cardiovascular outcomes and adverse events were evaluated over 5 years using Cox proportional hazards models.
Results
Individuals with obesity treated with GLP‐1 RAs plus aspirin showed significantly higher risks of various cardiovascular events compared to those on GLP‐1 RAs alone. In non‐diabetic obese individuals, the combination therapy increased risks of hypertensive heart diseases (HR 1.40, 95% CI 1.15–1.60), ischaemic heart disease (HR 2.39, 95% CI 1.92–2.97) and heart failure (HR 1.97, 95% CI 1.54–2.53). Similar patterns were observed in individuals with T2D. Atrial fibrillation and cardiac arrhythmias showed increasing hazard ratios over time. The combination therapy also led to more frequent adverse events, including gastrointestinal bleeding.
Conclusions
The combination of GLP‐1 RAs with aspirin in individuals with obesity, both with and without T2D, was associated with increased cardiovascular risks compared to GLP‐1 RA monotherapy. These findings suggest that there may be risks associated with the combined use of these treatments and highlight the need for further research into this possible complication with regard to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- School of Health and Society, University of Wollongong, Wollongong, New South Wales, Australia.
ORCID-Profile: Yu-Nan Huang
Förderung
- Chung Shan Medical University Hospital
Zitieren
APA
Lin, C. M., Chen, J. C., Meyerowitz-Katz, G., Huang, Y. N., & Su, P. H. (2025). Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16191
Vancouver
Lin CM, Chen JC, Meyerowitz-Katz G, Huang YN, Su PH. Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16191
BibTeX
@article{Lin2025,
author = {Lin, Chia-Ming and Chen, Jo-Ching and Meyerowitz-Katz, Gideon and Huang, Yu-Nan and Su, Pen-Hua},
title = {Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16191}
}
EUVIMED